

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Denintuzumab mafodotin is an antibody-drug conjugate that _____.
 - Comprises an anti-CD19 antibody conjugated to monomethyl auristatin F
 - Elicited a 30% to 40% response rate for patients with relapsed/refractory NHL
 - Is associated with a generally reversible corneal toxicity
 - All of the above
 - Both b and c
- A Phase I study of dose-adjusted TEDDI-R with ibrutinib produced promising results for patients with primary CNS lymphoma in both previously untreated and relapsed/refractory settings.
 - True
 - False
- The Phase III CALGB-10603 (RATIFY) trial evaluating midostaurin in combination with daunorubicin/cytarabine induction therapy and cytarabine consolidation and as maintenance for patients with newly diagnosed AML with FLT3 mutations demonstrated a statistically significant improvement in _____ on the midostaurin arm.
 - Median overall survival
 - Grade ≥ 3 hematologic adverse events
 - Both a and b
 - Neither a nor b
- Which of the following is the mechanism of action of gilteritinib (ASP2215)?
 - Demethylating agent
 - FLT3 inhibitor
 - IMiD
- Ixazomib is an oral proteasome inhibitor that recently received FDA approval for use in combination with lenalidomide and dexamethasone for the treatment of MM in patients who have received _____.
 - No previous therapy
 - At least 1 prior therapy
 - At least 2 prior therapies
 - At least 3 prior therapies
- The results of the Phase III PANORAMA-1 trial of panobinostat or placebo in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory MM demonstrated a statistically significant difference in _____ in favor of the panobinostat arm.
 - Median PFS
 - Overall response rate
 - Both a and b
- _____ is a monoclonal antibody that was recently FDA approved as a single agent for the treatment of MM in patients who have received at least 3 prior therapies.
 - Elotuzumab
 - Daratumumab
 - Both a and b
- The Phase II CheckMate 205 study evaluating the efficacy of nivolumab in relapsed/refractory classical HL demonstrated a 6-month overall survival rate of approximately _____.
 - 50%
 - 70%
 - 100%
- The Phase II SWOG-S1106 study evaluating BR versus R-hyper-CVAD followed by ASCT for patients with MCL was closed prematurely due to which of the following reasons?
 - Significantly higher overall response rate with BR than with R-hyper-CVAD
 - Predetermined criteria of stem cell mobilization failures on the R-hyper-CVAD arm
 - Both a and b
 - Neither a nor b
- The Phase II ECOG-E1411 study for elderly patients with previously untreated MCL is evaluating BR alone or in combination with bortezomib followed by consolidation therapy with rituximab alone or in combination with _____.
 - Idelalisib
 - Bortezomib
 - Lenalidomide